- Home
- ·
- VENTURES & DISCLOSURES
Ventures & disclosures
Professor Finlay works at the frontier of medical technology. In the interests of full transparency, his companies, roles and financial disclosures are listed here.
FOUNDED 2018 · UCL SPIN-OUT
UCL spin-out developing transformative interventional tools for coronary intervention — the iKOr system and flow-sensing microcatheter. £2.8M+ raised.
Founder · Director & Chief Medical Officer
FOUNDED 2018 · BARTS HEALTH SPIN-OUT
Barts Health spin-out developing new methods to target areas for more efficient, effective AF ablation — the STAR Mapping™ approach, with licensed patents.
Founder · Non-Executive Director
CO-FOUNDED · EDUCATION TECHNOLOGY
The world’s first web-delivered whole-heart electrical simulation for teaching and training — used in medical schools worldwide and licensed by Boston Scientific.
Co-founder
Radnor Medical Ltd
FOUNDED 2026 · DIGITAL HEALTH
Professor Finlay’s new venture in cardiac digital health — a patient app and clinic platform now in development, with the website launching soon.
Founder · Sole Owner
Ownership & interests
In line with regulatory requirements, Professor Finlay holds a financial interest in Radnor Medical Ltd (sole owner). Professor Finlay holds financial interests in Welbeck London Heart Health (3.36% ownership) & Welbeck London Imaging and Diagnostics (0.13% ownership). Professor Finlay's investment in Welbeck London Heart Health includes a group shareholding of 5% in Welbeck London Pharmacy for that relevant Speciality Group. This information is provided in the interests of transparency and to support informed patient choice.
Financial disclosures
Professor Finlay has received research funding, grants, travel support, educational support, lecture and consultancy fees from Biosense Webster (J&J) Ltd, Abbott Ltd, Medtronic Ltd and Biotronik GmbH, amongst others. These relationships never influence individual treatment decisions, which are always made in your best interests and agreed with you.
£5M+
raised across ventures
3
medtech companies founded
2
licensed patent families
Global
simulation used worldwide
What this means for you as a patient
First access to new techniques
Treatments like pulsed field ablation reach Professor Finlay’s patients early.
Deep technical understanding
A clinician who helps build the technology understands exactly how to use it.
Full transparency
Every commercial relationship is declared — decisions are made only in your interest.
Research, publications & ventures
See Professor Finlay’s published research and the companies he has founded.